Clinical Trials
51 trialsNCT06520345 2026-05-27
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT06925737 2026-05-22
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07213674 2026-05-22
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
NCT03574571 2026-05-14
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT06931340 2026-05-08
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06764485 2026-05-06
rechARge
Celgene
Phase 3 Recruiting
NCT06551324 2026-05-05
MEVPRO-1
Pfizer
Phase 3 Active not recruiting
NCT06439225 2026-04-16
OPTION-DDR
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06592924 2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT07333066 2026-01-12
REINFORCE
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase 3 Not yet recruiting
NCT03678025 2025-09-11
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
Phase 3 Recruiting
NCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04100018 2025-06-12
CheckMate 7DX
Bristol-Myers Squibb
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT05676203 2025-02-17
ARASAFE
Jena University Hospital
Phase 3 Active not recruiting
NCT05348577 2025-01-27
CAPItello280
AstraZeneca
Phase 3 Active not recruiting
NCT01957436 2024-11-12
PEACE1
UNICANCER
Phase 3 Active not recruiting
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT05983783 2023-08-09
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Recruiting
NCT00651326 2023-08-04
DART
Canadian Cancer Trials Group
Phase 3 Terminated
NCT00027859 2023-06-15
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00430183 2023-02-09
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT00055731 2023-01-18
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
UNICANCER
Phase 3 Completed
NCT00288080 2022-06-21
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00116142 2022-01-11
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Dana-Farber Cancer Institute
Phase 3 Completed
NCT00134056 2021-10-27
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
SWOG Cancer Research Network
Phase 3 Completed
NCT03119857 2021-08-18
Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14
Göteborg University
Phase 3 Unknown
NCT00653848 2021-03-25
AdRad
Scandinavian Prostate Cancer Group
Phase 3 Unknown
NCT00104715 2021-02-21
Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
UNICANCER
Phase 3 Completed
NCT00030654 2020-10-22
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01308567 2019-06-05
FIRSTANA
Sanofi
Phase 3 Completed
NCT00132301 2018-06-25
CAP
VA Office of Research and Development
Phase 3 Completed
NCT00988208 2018-04-04
Mainsail
Celgene
Phase 3 Completed
NCT00744497 2016-10-17
READY
Bristol-Myers Squibb
Phase 3 Completed
NCT01188187 2016-10-14
SYNERGY
Achieve Life Sciences
Phase 3 Completed
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT00041171 2016-07-12
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Withdrawn
NCT00024167 2016-03-22
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00110214 2014-05-09
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 3 Completed
NCT00004001 2014-02-25
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
SWOG Cancer Research Network
Phase 3 Completed
NCT00514917 2013-11-04
Rising PSA
Sanofi
Phase 3 Terminated
NCT00376792 2013-08-26
Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00796458 2013-08-12
Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00255606 2013-06-26
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00617669 2012-09-10
ENTHUSE M1C
AstraZeneca
Phase 3 Completed
NCT00436839 2012-07-09
Taxotere Prostate Cancer New Indication Registration Trial in China
Sanofi
Phase 3 Completed
NCT00283062 2012-01-26
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
Sanofi
Phase 3 Completed
NCT00705822 2010-11-30
PROSTATA
Sanofi
Phase 3 Terminated
NCT00089856 2008-11-05
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
Cell Genesys
Phase 3 Terminated
NCT00133224 2008-09-23
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
Cell Genesys
Phase 3 Terminated